STM-416

SURGE Therapeutics · Phase 1 active Small molecule

At a glance

Generic name	STM-416
Sponsor	SURGE Therapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy (PHASE1)
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

STM-416 CI brief — competitive landscape report
STM-416 updates RSS · CI watch RSS
SURGE Therapeutics portfolio CI